Clinical and economic impact of medication reconciliation by designated ward pharmacists in a hospitalist-managed acute medical unit

Minimizing unintended medication errors after admission is a common goal for clinical pharmacists and hospitalists. We assessed the clinical and economic impact of a medication reconciliation service in a model of designated ward pharmacists working in a hospitalist-managed acute medical unit as par...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Research in social and administrative pharmacy 2022-04, Vol.18 (4), p.2683-2690
Hauptverfasser: Park, Bogeum, Baek, Anna, Kim, Yoonhee, Suh, Yewon, Lee, Jungwha, Lee, Eunsook, Lee, Ju-Yeun, Lee, Euni, Lee, Jongchan, Park, Hee Sun, Kim, Eun Sun, Lim, Yejee, Kim, Nak-Hyun, Ohn, Jung Hun, Kim, Hye Won
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Minimizing unintended medication errors after admission is a common goal for clinical pharmacists and hospitalists. We assessed the clinical and economic impact of a medication reconciliation service in a model of designated ward pharmacists working in a hospitalist-managed acute medical unit as part of a multidisciplinary team. In this retrospective observational study, we compared pharmacist intervention records before and after the implementation of a medication reconciliation service by designated pharmacists. The frequency and type of intervention were assessed and their clinical impact was estimated according to the length of hospital stay and 30-day readmission rate. A cost analysis was performed using the average hourly salary of a pharmacist, cost of interventions (time spent on interventions), and cost avoidance (avoided costs generated by interventions). After the implementation of the medication reconciliation service, the frequency of pharmacist interventions increased from 3.9% to 22.1% (p 
ISSN:1551-7411
1934-8150
DOI:10.1016/j.sapharm.2021.06.005